Swedish study confirms no loss of immunity after 18 years of HPV vaccination, with women vaccinated young showing almost 80% protection.
A landmark Swedish study published today in The BMJ provides reassuring evidence that human papillomavirus (HPV) vaccination delivers long-lasting protection against invasive cervical cancer, with no decline in protection over 18 years of follow-up.
The research, conducted by Karolinska Institutet in collaboration with Swedish health authorities, tracked more than 926,000 girls and women born between 1985 and 2001. Of these, 365,000 had received the HPV vaccine, whilst the remainder served as a comparison group. During the study period, 930 participants developed invasive cervical cancer—97 of whom had been vaccinated.
Outstanding Protection in Young Vaccinees
The findings are particularly encouraging for women vaccinated during their early teens. Those who received the vaccine before age 17 showed an almost 80% lower risk of developing cervical cancer compared to unvaccinated women. Even those vaccinated later—in their late teens and early adulthood—demonstrated significant protective benefit.
Critically, researchers found no evidence of the protection wearing off over the nearly two decades of observation. “It is encouraging that the protection persists as young girls become adults and reach the ages when cervical cancer often occurs,” said Shiqiang Wu, a doctoral researcher at Karolinska Institutet. “This suggests that no booster doses of the HPV vaccine are needed at present.”
The study examined the quadrivalent HPV vaccine, which protects against four strains of the virus responsible for the majority of cervical cancers. This represents the largest and longest follow-up study to date examining the vaccine’s real-world effectiveness.
The Impact of School-Based Vaccination Programmes
The research also highlighted the vital importance of vaccinating young people through school health services. Women who were offered vaccination through their school programmes showed a 72% lower risk of cervical cancer compared to older age groups who had to access the vaccine outside routine public health provision.
“When vaccination is offered in schools, more people are reached, and our results show how important this is for reducing the risk of cervical cancer in the entire population,” Wu explained. The findings underscore why national vaccination programmes targeting schoolchildren are more effective at population level than relying on opportunistic vaccination in clinical settings.
Context from UK Implementation
The Swedish findings align with established evidence from the NHS cervical screening programme in England. Research published by the UK Health Security Agency has demonstrated similarly impressive results, with the English HPV vaccination scheme preventing an estimated 687 cervical cancer cases and more than 23,000 cases of pre-cancerous changes (cervical intraepithelial neoplasia grade 3, or CIN3) by 2020 alone.
In England, HPV vaccination was introduced nationally in 2008 and is routinely offered to girls aged 12–13 years. The vaccine has become part of the standard childhood immunisation schedule, with catch-up campaigns previously offered to older teenagers. Boys have been included in the routine programme since 2019, reflecting understanding that HPV vaccination protects against other cancers in men as well as women.
What the Research Tells Us
HPV, or human papillomavirus, is a sexually transmitted infection present in over 80% of sexually active people at some point in their lives. Whilst most HPV infections clear naturally, persistent infection with certain high-risk strains can progress to cervical cancer and other cancers. The vaccine works by preventing infection with these high-risk strains before exposure occurs—hence the emphasis on vaccination before sexual activity begins.
The Swedish study population and follow-up period allowed researchers to observe women moving through their twenties and into their thirties, the ages when cervical cancer typically develops following persistent HPV infection. The sustained protection observed in this real-world setting is significant because it answers a key question about vaccine durability that has long concerned public health officials.
Researchers acknowledged study limitations, noting that factors such as lifestyle and sexual behaviour were not recorded in health registries, and that they could not determine which specific HPV strain caused each cancer case. Nevertheless, the large population size and extended follow-up period provide compelling evidence of the vaccine’s effectiveness in preventing disease in everyday practice.
What This Means for Kent Residents
For Kent residents, these findings reinforce the importance of the HPV vaccination programme delivered through Kent schools. Parents of 12–13-year-old children should ensure their son or daughter receives the vaccine, which is safe, effective, and free on the NHS. Young people aged 14–25 who were not vaccinated earlier can still access free catch-up vaccination through sexual health and contraception services.
Those with concerns about HPV vaccination or questions about whether it is suitable for their circumstances should speak with their GP or local sexual health clinic. The evidence now spanning nearly two decades confirms that this vaccine is one of the most effective cancer prevention tools available to the NHS.
Source: @bmj_latest
Key Takeaways
- HPV vaccination provides sustained protection against cervical cancer for at least 18 years with no sign of waning immunity
- Young people vaccinated before age 17 achieved almost 80% protection compared to unvaccinated individuals
- School-based vaccination programmes deliver population-level benefits by reaching more young people
- The long-term Swedish data supports findings from the English NHS vaccination programme
What This Means for Kent Residents
The publication of this Swedish study provides additional confidence for parents and young people in Kent considering or already having received the HPV vaccine. The NHS in Kent and Medway continues to offer free HPV vaccination to all eligible schoolchildren and catch-up vaccination to young adults up to age 25. Anyone with questions about the vaccine should contact their GP surgery, school nurse, or local sexual health service. The accumulated evidence—now including nearly two decades of real-world protection data—confirms that HPV vaccination remains one of the most effective preventive health interventions available.
